Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Jul;38(7):1580–1587. doi: 10.1128/aac.38.7.1580

Pharmacokinetics and safety of weekly dapsone and dapsone plus pyrimethamine for prevention of pneumocystis pneumonia.

J Falloon 1, J Lavelle 1, D Ogata-Arakaki 1, A Byrne 1, A Graziani 1, A Morgan 1, M A Amantea 1, K Ownby 1, M Polis 1, R T Davey Jr 1, et al.
PMCID: PMC284596  PMID: 7979291

Abstract

The safety and pharmacokinetics of weekly dapsone and weekly dapsone plus pyrimethamine were examined in adult patients with human immunodeficiency virus infection who were at risk for pneumocystis pneumonia because of a prior episode or a CD4+ T-cell count less than 250 cells per mm3. Groups of patients received 100, 200, and 300 mg of dapsone as a single weekly dose. The maximum tolerated dose of weekly dapsone was established as 200 mg per week in patients receiving at least 500 mg of zidovudine concomitantly. This dose of dapsone was then found to be well tolerated when combined with pyrimethamine at 25 mg. Further patients were randomized to dapsone at 200 mg or dapsone at 200 mg plus pyrimethamine at 25 mg once weekly. Twenty-six patients each were followed for a median of 33 weeks on dapsone alone and 45 weeks on the combination. Seven patients in each group withdrew because of toxicity. Five patients receiving dapsone developed documented pneumocystis pneumonia, while four and two patients receiving dapsone plus pyrimethamine developed documented and presumptive pneumocystis pneumonia, respectively. To evaluate the tolerability of a higher dose of pyrimethamine, 11 patients had their regimen changed to dapsone at 200 mg plus pyrimethamine at 75 mg, which was well tolerated by 10 of the patients for a median period of 11 weeks. The pharmacokinetics of dapsone and pyrimethamine were examined by using a population pharmacokinetic model. Decreases in the apparent volume of the peripheral compartment were observed when multiple-dose regimens of dapsone were compared with single-dose dapsone and when multiple-dose regimens of dapsone with pyrimethamine were compared with multiple-dose dapsone alone. When administered weekly, dapsone at 200 mg and dapsone at 200 mg with pyrimethamine at 25 mg are both well-tolerated regimens. This preliminary study suggests that the efficacy of these regimens in preventing pneumocystis pneumonia, however, may be less than that of trimethoprim-sulfamethoxazole.

Full text

PDF
1580

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahmad R. A., Rogers H. J. Pharmacokinetics and protein binding interactions of dapsone and pyrimethamine. Br J Clin Pharmacol. 1980 Nov;10(5):519–524. doi: 10.1111/j.1365-2125.1980.tb01798.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Allegra C. J., Boarman D., Kovacs J. A., Morrison P., Beaver J., Chabner B. A., Masur H. Interaction of sulfonamide and sulfone compounds with Toxoplasma gondii dihydropteroate synthase. J Clin Invest. 1990 Feb;85(2):371–379. doi: 10.1172/JCI114448. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Allegra C. J., Kovacs J. A., Drake J. C., Swan J. C., Chabner B. A., Masur H. Activity of antifolates against Pneumocystis carinii dihydrofolate reductase and identification of a potent new agent. J Exp Med. 1987 Mar 1;165(3):926–931. doi: 10.1084/jem.165.3.926. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Antinori A., Murri R., Tamburrini E., De Luca A., Ortona L. Failure of low-dose dapsone-pyrimethamine in primary prophylaxis of Pneumocystis carinii pneumonia. Lancet. 1992 Sep 26;340(8822):788–788. doi: 10.1016/0140-6736(92)92326-b. [DOI] [PubMed] [Google Scholar]
  5. Blum R. N., Miller L. A., Gaggini L. C., Cohn D. L. Comparative trial of dapsone versus trimethoprim/sulfamethoxazole for primary prophylaxis of Pneumocystis carinii pneumonia. J Acquir Immune Defic Syndr. 1992;5(4):341–347. [PubMed] [Google Scholar]
  6. Carr K., Oates J. A., Nies A. S., Woosley R. L. Simultaneous analysis of dapsone and monoacetyldapsone employing high performance liquid chromatography: a rapid method for determination of acetylator phenotype. Br J Clin Pharmacol. 1978 Nov;6(5):421–427. doi: 10.1111/j.1365-2125.1978.tb04606.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Clotet B., Sirera G., Romeu J., Gimeno J. M., Jou A., Condom M. J., Tor J., Foz M. Twice-weekly dapsone-pyrimethamine for preventing PCP and cerebral toxoplasmosis. AIDS. 1991 May;5(5):601–602. [PubMed] [Google Scholar]
  8. Coker R. J., Nieman R., McBride M., Mitchell D. M., Harris J. R., Weber J. N. Co-trimoxazole versus dapsone-pyrimethamine for prevention of Pneumocystis carinii pneumonia. Lancet. 1992 Oct 31;340(8827):1099–1099. doi: 10.1016/0140-6736(92)93120-c. [DOI] [PubMed] [Google Scholar]
  9. D'Argenio D. Z., Schumitzky A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed. 1979 Mar;9(2):115–134. doi: 10.1016/0010-468x(79)90025-4. [DOI] [PubMed] [Google Scholar]
  10. Girard P. M., Landman R., Gaudebout C., Olivares R., Saimot A. G., Jelazko P., Gaudebout C., Certain A., Boué F., Bouvet E. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group. N Engl J Med. 1993 May 27;328(21):1514–1520. doi: 10.1056/NEJM199305273282102. [DOI] [PubMed] [Google Scholar]
  11. Hardy W. D., Feinberg J., Finkelstein D. M., Power M. E., He W., Kaczka C., Frame P. T., Holmes M., Waskin H., Fass R. J. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. N Engl J Med. 1992 Dec 24;327(26):1842–1848. doi: 10.1056/NEJM199212243272604. [DOI] [PubMed] [Google Scholar]
  12. Hughes W. T. Comparison of dosages, intervals, and drugs in the prevention of Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1988 May;32(5):623–625. doi: 10.1128/aac.32.5.623. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hughes W. T., Kennedy W., Dugdale M., Land M. A., Stein D. S., Weems J. J., Jr, Palte S., Lancaster D., Gidan-Kovnar S., Morrison R. E. Prevention of Pneumocystis carinii pneumonitis in AIDS patients with weekly dapsone. Lancet. 1990 Oct 27;336(8722):1066–1066. doi: 10.1016/0140-6736(90)92533-n. [DOI] [PubMed] [Google Scholar]
  14. Kemper C. A., Tucker R. M., Lang O. S., Kessinger J. M., Greene S. I., Deresinski S. C., Stevens D. A. Low-dose dapsone prophylaxis of Pneumocystis carinii pneumonia in AIDS and AIDS-related complex. AIDS. 1990 Nov;4(11):1145–1148. doi: 10.1097/00002030-199011000-00015. [DOI] [PubMed] [Google Scholar]
  15. Lee B. L., Medina I., Benowitz N. L., Jacob P., 3rd, Wofsy C. B., Mills J., 5th Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Evidence of drug interactions. Ann Intern Med. 1989 Apr 15;110(8):606–611. doi: 10.7326/0003-4819-110-8-606. [DOI] [PubMed] [Google Scholar]
  16. Lucas C. R., Sandland A. M., Mijch A., Simpson J. M. Primary dapsone chemoprophylaxis for Pneumocystis carinii pneumonia in immunocompromised patients infected with the human immunodeficiency virus. Med J Aust. 1989 Jul 3;151(1):30–33. doi: 10.5694/j.1326-5377.1989.tb128450.x. [DOI] [PubMed] [Google Scholar]
  17. Mallolas J., Zamora L., Gatell J. M., Miró J. M., Soriano E. Low-dose co-trimoxazole, aerosolised pentamidine, or dapsone plus pyrimethamine for prevention of Pneumocystis carinii pneumonia. Lancet. 1991 May 11;337(8750):1162–1163. doi: 10.1016/0140-6736(91)92829-q. [DOI] [PubMed] [Google Scholar]
  18. Martin M. A., Cox P. H., Beck K., Styer C. M., Beall G. N. A comparison of the effectiveness of three regimens in the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients. Arch Intern Med. 1992 Mar;152(3):523–528. [PubMed] [Google Scholar]
  19. Metroka C. E., McMechan M. F., Andrada R., Laubenstein L. J., Jacobus D. P. Failure of prophylaxis with dapsone in patients taking dideoxyinosine. N Engl J Med. 1991 Sep 5;325(10):737–737. doi: 10.1056/nejm199109053251014. [DOI] [PubMed] [Google Scholar]
  20. Phair J., Muñoz A., Detels R., Kaslow R., Rinaldo C., Saah A. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med. 1990 Jan 18;322(3):161–165. doi: 10.1056/NEJM199001183220304. [DOI] [PubMed] [Google Scholar]
  21. Slavin M. A., Hoy J. F., Stewart K., Pettinger M. B., Lucas C. R., Kent S. J. Oral dapsone versus nebulized pentamidine for Pneumocystis carinii pneumonia prophylaxis: an open randomized prospective trial to assess efficacy and haematological toxicity. AIDS. 1992 Oct;6(10):1169–1174. [PubMed] [Google Scholar]
  22. Steimer J. L., Mallet A., Golmard J. L., Boisvieux J. F. Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model. Drug Metab Rev. 1984;15(1-2):265–292. doi: 10.3109/03602538409015066. [DOI] [PubMed] [Google Scholar]
  23. Torres R. A., Barr M., Thorn M., Gregory G., Kiely S., Chanin E., Carlo C., Martin M., Thornton J. Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. Am J Med. 1993 Dec;95(6):573–583. doi: 10.1016/0002-9343(93)90352-p. [DOI] [PubMed] [Google Scholar]
  24. Zuidema J., Hilbers-Modderman E. S., Merkus F. W. Clinical pharmacokinetics of dapsone. Clin Pharmacokinet. 1986 Jul-Aug;11(4):299–315. doi: 10.2165/00003088-198611040-00003. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES